Cancers of the blood account for an estimated 8% of all cancers in adults, with 5-year survival projections as low as 47%. Treatment costs can surpass $800,000 in acute cases, with an average of $200,000 spent during the first two years of treatment. As the population ages, doctors anticipate a rise in the number of hematological malignancies and an increased demand for safe, effective means of treating these difficult-to-treat cancers. Chimeric antigen receptor (CAR) T cells are an emerging technology that have revolutionized cancer treatment, but an estimated 50% of patients do not respond to CAR T cell therapy. In nearly half of these cases failure is due to decreased persistence of the re-infused cells.